Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
Categories
Amines
Antineoplastic Agents
Antineoplastic and Immunomodulating Agents
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 CYP2D6 Inhibitors (moderate)
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Enzyme Inhibitors
Heterocyclic Compounds, Fused-Ring
Histone deacetylase (HDAC) inhibitors
Histone Deacetylase Inhibitors
Hydroxamic Acids
Hydroxy Acids
Hydroxylamines
Immunosuppressive Agents
Indoles
Moderate Risk QTc-Prolonging Agents
Narrow Therapeutic Index Drugs
P-glycoprotein substrates
P-glycoprotein substrates with a Narrow Therapeutic Index
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
